Risk of death due to stroke may be increased in women with coronary heart disease or in women at risk for coronary events (use with caution in cardiovascular disease). Do not use for prevention of cardiovascular disease. Use with caution in history of cervical/uterine carcinoma, and in hepatic impairment. Women with history of elevated triglycerides in response to treatment with oral estrogens (or estrogen/progestin) may develop elevated triglycerides when treated with raloxifene. Use with caution in moderate-to-severe renal impairment. May increase risk for DVT or PE (use with caution in patients at high risk for venous thromboembolism). Use contraindicated in history of or current venous thromboembolic disorders. Use with caution in unexplained uterine bleeding. Use with systemic estrogen therapy not recommended. Not indicated for treatment of invasive breast cancer, reduction of risk of recurrence of invasive breast cancer, or reduction of risk of noninvasive breast cancer. Efficacy (for breast cancer risk reduction) in women with inherited BRCA1 and BRCA1 mutations not established. Discontinue at least 72 hours prior to and during prolonged immobilization (postoperative recovery or prolonged bedrest).